-
Uncategorized2 months ago
Nektar’s $325M offering; Maze stock rises; Merck deal rumors; BMS layoffs
Nektar Therapeutics prices $325 million public offering: The Bay Area biotech is selling about 3.5 million shares of stock at $92 per share. The proceeds will...
-
Uncategorized2 months ago
Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy
Sanofi’s new CEO faces a reckoning on immunology-focused R&D strategy
-
Uncategorized2 months agoModerna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage...
-
Uncategorized2 months ago
Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients
With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead...
-
Uncategorized2 months ago
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the...
-
Uncategorized2 months agoTipping the genomic scales: Preparing for the integrated multiomics era
This paid-for advertorial by Sampled appeared in DDW Volume 27 – Issue 2, Spring 2026 How sequencing innovation and integrated workflows are enabling reproducible multiomic studies. Genomics has...
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about Medicare’s obesity drug pilot, an experimental Roche MS drug, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days...
-
Uncategorized2 months ago
The 4 biggest hiring mistakes biopharma executives keep making
The 4 biggest hiring mistakes biopharma executives keep making
-
Uncategorized2 months ago
Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision
The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and...
-
Uncategorized2 months ago
Lilly exits Rigel alliance, adding to RIPK1 scrap heap
Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug...
